$YTENQ
YIELD10 BIOSCIENCE, INC.

2023 Q3 Form 10-Q Financial Statement

#000112170223000046 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.499M $1.670M
YoY Change -1.25% 9.65%
% of Gross Profit
Research & Development $2.200M $1.997M
YoY Change 5.62% -0.94%
% of Gross Profit
Depreciation & Amortization $70.00K $76.00K
YoY Change 1.45% 10.14%
% of Gross Profit
Operating Expenses $1.499M $1.670M
YoY Change -1.25% 9.65%
Operating Profit -$3.703M -$3.667M
YoY Change 6.1% 6.72%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$23.00K -$14.00K
YoY Change -330.0% -800.0%
Pretax Income -$3.726M -$3.681M
YoY Change 7.07% 7.19%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.726M -$3.681M
YoY Change 6.79% 6.91%
Net Earnings / Revenue
Basic Earnings Per Share -$0.41 -$0.64
Diluted Earnings Per Share -$0.41 -$0.64
COMMON SHARES
Basic Shares Outstanding 6.114M shares 5.729M shares
Diluted Shares Outstanding 8.988M shares 5.729M shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.800M $2.336M
YoY Change -62.19% -77.0%
Cash & Equivalents $2.817M $2.336M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $500.0K $689.0K
YoY Change 20.77% 42.65%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $3.362M $3.025M
YoY Change -57.42% -71.74%
LONG-TERM ASSETS
Property, Plant & Equipment $594.0K $663.0K
YoY Change -29.29% -25.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $53.00K $67.00K
YoY Change -74.76% -72.98%
Total Long-Term Assets $2.680M $2.845M
YoY Change -20.64% -20.29%
TOTAL ASSETS
Total Short-Term Assets $3.362M $3.025M
Total Long-Term Assets $2.680M $2.845M
Total Assets $6.042M $5.870M
YoY Change -46.4% -58.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $381.0K $467.0K
YoY Change 266.35% 1845.83%
Accrued Expenses $1.944M $1.375M
YoY Change 67.15% 29.84%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.000M
YoY Change
Total Short-Term Liabilities $3.953M $2.470M
YoY Change 116.48% 51.81%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $971.0K
YoY Change
Other Long-Term Liabilities $1.700M $1.842M
YoY Change -23.63% -22.44%
Total Long-Term Liabilities $1.700M $2.813M
YoY Change -23.63% 18.44%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.953M $2.470M
Total Long-Term Liabilities $1.700M $2.813M
Total Liabilities $5.650M $5.283M
YoY Change 39.44% 32.01%
SHAREHOLDERS EQUITY
Retained Earnings -$410.9M -$407.2M
YoY Change 3.66% 3.63%
Common Stock $411.5M $408.0M
YoY Change 1.9% 1.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $392.0K $587.0K
YoY Change
Total Liabilities & Shareholders Equity $6.042M $5.870M
YoY Change -46.4% -58.87%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$3.726M -$3.681M
YoY Change 6.79% 6.91%
Depreciation, Depletion And Amortization $70.00K $76.00K
YoY Change 1.45% 10.14%
Cash From Operating Activities -$2.610M -$3.079M
YoY Change -3.4% 21.32%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $18.00K
YoY Change -100.0% -194.74%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $10.00K -$18.00K
YoY Change -99.71% -100.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.090M 3.638M
YoY Change -13534.78%
NET CHANGE
Cash From Operating Activities -2.610M -3.079M
Cash From Investing Activities 10.00K -18.00K
Cash From Financing Activities 3.090M 3.638M
Net Change In Cash 490.0K 541.0K
YoY Change -36.28% -49.81%
FREE CASH FLOW
Cash From Operating Activities -$2.610M -$3.079M
Capital Expenditures $0.00 $18.00K
Free Cash Flow -$2.610M -$3.097M
YoY Change -2.65% 22.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
971000 usd
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 usd
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4944202 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4944202 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.38
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4894638 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4894638 shares
CY2023Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
26000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
13000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-12000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3681000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
587000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
13211000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
489000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
41000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-27000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3443000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
10271000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4400000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
805000 usd
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
56000 usd
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
41000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
25000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-15000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7463000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
587000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
16026000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1012000 usd
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
66000 usd
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
14000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-45000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6774000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
10271000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2336000 usd
CY2023Q2 yten Sale Of Stock Maximum Shares
SaleOfStockMaximumShares
931600 shares
CY2023Q2 yten Equity Issuance Costs Payable
EquityIssuanceCostsPayable
88000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2336000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2356000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
264000 usd
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
264000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2600000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2620000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
264000 usd
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
264000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;padding-right:4.5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of grant revenue and expenses during the reporting periods. Actual results could differ from those estimates.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, restricted cash, short-term investments and accounts receivable. The Company has historically invested its </span></div>cash in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company’s investment policy which establishes a concentration limit per issuer.
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3293359 shares
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2294407 shares
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1992000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1991000 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
276000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
39000 usd
CY2023Q2 yten Accrued Lease Cost
AccruedLeaseCost
58000 usd
CY2022Q4 yten Accrued Lease Cost
AccruedLeaseCost
81000 usd
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
430000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
264000 usd
CY2023Q2 yten Accrued Field Trials And Related Expenses Current
AccruedFieldTrialsAndRelatedExpensesCurrent
366000 usd
CY2022Q4 yten Accrued Field Trials And Related Expenses Current
AccruedFieldTrialsAndRelatedExpensesCurrent
146000 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
245000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
396000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1375000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
926000 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
394000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
830000 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
488000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1011000 usd
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2771000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M17D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
247210 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
244092 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
166702 shares
CY2021Q1 yten Share Based Compensation Arrangement By Share Based Payment Award Additional Shares Authorized Percent
ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent
0.05
CY2022Q1 yten Share Based Compensation Arrangement By Share Based Payment Award Additional Shares Authorized Percent
ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent
0.05
CY2023Q1 yten Share Based Compensation Arrangement By Share Based Payment Award Additional Shares Authorized Percent
ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent
0.05
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
500000 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
569538 shares
us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
9483 shares
yten Payment Tax Withholding Share Based Payment Arrangement Excluding Employer Amount
PaymentTaxWithholdingShareBasedPaymentArrangementExcludingEmployerAmount
34000 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
150000 usd
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
151000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
301000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
303000 usd
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
181000 usd
CY2022Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
183000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
398000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
332000 usd
CY2023Q2 us-gaap Sublease Income
SubleaseIncome
177000 usd
CY2022Q2 us-gaap Sublease Income
SubleaseIncome
153000 usd
us-gaap Sublease Income
SubleaseIncome
336000 usd
us-gaap Sublease Income
SubleaseIncome
295000 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
154000 usd
CY2022Q2 us-gaap Lease Cost
LeaseCost
181000 usd
us-gaap Lease Cost
LeaseCost
363000 usd
us-gaap Lease Cost
LeaseCost
340000 usd
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y10M24D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0745
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0725
CY2016Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
22213 sqft
CY2023Q2 yten Letter Of Intent Exclusivity Period
LetterOfIntentExclusivityPeriod
P120D
CY2023Q2 yten Letter Of Intent Exclusivity Period
LetterOfIntentExclusivityPeriod
P120D
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
103000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
60000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
252000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
663000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
895000 usd
CY2023Q2 yten Sale Of Stock Maximum Shares
SaleOfStockMaximumShares
931600 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
2.98
CY2023Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
2.9799
CY2023Q2 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
75110 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
5558 shares
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
10030 shares
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
13000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
25000 usd
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2136008 shares
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3293359 shares
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2136169 shares

Files In Submission

Name View Source Status
yten-20230630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
yten-20230630_pre.xml Edgar Link unprocessable
0001121702-23-000046-index-headers.html Edgar Link pending
0001121702-23-000046-index.html Edgar Link pending
0001121702-23-000046.txt Edgar Link pending
0001121702-23-000046-xbrl.zip Edgar Link pending
ex-311x20230630.htm Edgar Link pending
ex-312x20230630.htm Edgar Link pending
ex-321x20230630.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
yten-20230630.htm Edgar Link pending
yten-20230630.xsd Edgar Link pending
yten-20230630_def.xml Edgar Link unprocessable
yten-20230630_lab.xml Edgar Link unprocessable
yten-20230630_htm.xml Edgar Link completed